Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurodex: Phase II/III

In a double-blind U.S. Phase II/III trial to treat emotional lability in 140 patients with amyotrophic

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE